Merck's stock ( MRK ) has soared by almost 30% since my previous bullish call , indicating robust share price momentum and increasing investors' confidence. I am not surprised because Merck's fundamentals are rock-solid with stellar financialI am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and intern ...

Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts. ...

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #100MostInfluentialAfricans--Dr. Rasha Kelej, CEO of Merck Foundation, has been recognized as one of the 100 Most Influential Africans by New African Magazine (UK). ...

默沙东公司1月7日宣布，其子公司已成功完成对Cidara Therapeutics公司全部流通普通股的现金要约收 购。2025年11月，默沙东与Cidara达成最终协议。根据协议，默沙东将通过子公司以每股221.50美元现 金收购Cidara，交易总金额约达92亿美元。（智通财经） ...

分组1 - Credo Technology (CRDO) has a high momentum rating despite a recent drop, with a current rating of B compared to A+ six months ago. The stock has shown significant performance over various periods, including a 101% increase over 12 months versus the sector's 0.36% [6][7][8] - Merck (MRK) is preferred over Pfizer (PFE) due to slightly better momentum and total returns, despite Pfizer having better valuation metrics. Merck's momentum is rated B- compared to Pfizer's C, and it has outperformed Pfizer in returns over the last month, three months, and six months [13][15] - Comfort Systems (FIX) is rated as a hold due to a poor valuation grade (F), despite strong growth (A+) and profitability (A-). The stock's trailing PE is 42 times compared to the sector's 21 times, indicating it is expensive [22][24][25] 分组2 - Energy stocks are sensitive to oil prices, which can lead to changes in fundamentals and ratings. For example, Energy Transfer (ET) has seen its rating drop from strong buy to hold due to declining oil prices [17][20] - The quant analysis system used evaluates stocks based on factors such as value, growth, profitability, momentum, and EPS revisions. Each factor has underlying metrics that are weighted based on their predictive value [31][34] - The top 10 stocks for 2026 have shown strong past performance, with returns significantly outperforming the S&P 500 over various periods. For instance, stocks held from 2024 to December 2025 yielded a return of 356% compared to the S&P's 47% [40][41]

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomi ...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEXâ"¢ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomi ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara†). "The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet,†said Robert M. Dav ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3. ...

Merck & Co., Inc. (MRK), based in Rahway, New Jersey, is a healthcare company. Valued at $264.2 billion by market cap, the company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The pharmaceutical giant is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Tuesday, Feb. 3. Ahead of the event, analysts expect MRK to repor ...